Themis Bioscience

Muthgasse 11/2
Vienna
1190

Tel: 43-1-236-7151
Fax: 43-1-236-7151-74

Website: http://www.themisbio.com/

Show jobs for this employer

About Themis Bioscience

Themis Bioscience is an international biotech company that successfully develops vaccines against emerging and specialist indications.
LEADERSHIP:
Founder and CEO: Erich Tauber
CFO: David A. Maier
CLINICAL TRIAL:
Please click here for clinical trial information.

29 articles with Themis Bioscience

Themis Release: Chikungunya Vaccine Development Towards Phase III Trials Boosted By Innovate UK

9/5/2017
Chikungunya-Fever: Themis Starts Phase II Clinical Study In Endemic Area

7/27/2017
Zika Virus: Themis Initiates Worldwide First Study With Live Attenuated Recombinant Vaccine

4/11/2017
Themis Successfully Closes 10 Million Eur Financing Round

11/28/2016
Themis Release: Zika Vaccine Development Receives Big Boost By Innovate UK

9/6/2016
Themis: Phase 2 Trial Of Leading Chikungunya Vaccine Candidate Started

8/25/2016
Two Renowned Vaccine Experts Joining Themis

1/19/2016
Themis’s Raises Up To EUR 10 Million In Series B

5/5/2015
Themis’s Chikungunya Vaccine Study Results Published In The Lancet Infectious Diseases

3/2/2015